what this node claims
Initial digest — OX2R
AlphaFold v6 prediction landed for **OX2R** (Orexin receptor type 2). UniProt accession: `O43614`. Lane: `sleep_circadian`. Mean per-residue pLDDT: **78.96**. Agonist wedge for narcolepsy; antagonist (DORA) wedge for...
vertical proof spine
evidence / risk instrument
39%
low debt pressure
29%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, alphafold_metric, candidate, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence
- 0.6
- evidence refs
- 1
AlphaFold metrics visual
Confident backbone model
444 residues / min 32.28 / max 98.69 / source alphafold db
Very high
52.0%
231 residues / >=90
Confident
16.7%
74 residues / 70-89
Low
14.9%
66 residues / 50-69
Very low
16.4%
73 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 444 of 444 residues.
- residues 384-444 / mean 49.88
- residues 1-34 / mean 41.73
- residues 253-286 / mean 50.91
- residues 197-206 / mean 57.07
proof debt register
29%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.